Ziresovir

Ziresovir

Ziresovir

Medication

Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.[1][2][3]

Quick Facts Clinical data, Trade names ...

See also

References

  1. [1]
    Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, et al. (July 2019). "Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor". Journal of Medicinal Chemistry. 62 (13): 6003–6014. doi:10.1021/acs.jmedchem.9b00654. PMID 31194544.
  2. [2]
    Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446. PMID 30974127.
  3. [3]
    Taylor, Nick Paul (7 April 2022). "ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data". Fierce Biotech. Retrieved 17 July 2022.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Ziresovir, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.